These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 37766136)

  • 1. Epidermal Growth Factor Receptor-Targeted Neoantigen Peptide Vaccination for the Treatment of Non-Small Cell Lung Cancer and Glioblastoma.
    Li F; Wu H; Du X; Sun Y; Rausseo BN; Talukder A; Katailiha A; Elzohary L; Wang Y; Wang Z; Lizée G
    Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations.
    Li F; Deng L; Jackson KR; Talukder AH; Katailiha AS; Bradley SD; Zou Q; Chen C; Huo C; Chiu Y; Stair M; Feng W; Bagaev A; Kotlov N; Svekolkin V; Ataullakhanov R; Miheecheva N; Frenkel F; Wang Y; Zhang M; Hawke D; Han L; Zhou S; Zhang Y; Wang Z; Decker WK; Sonnemann HM; Roszik J; Forget MA; Davies MA; Bernatchez C; Yee C; Bassett R; Hwu P; Du X; Lizee G
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme.
    Chistiakov DA; Chekhonin IV; Chekhonin VP
    Eur J Pharmacol; 2017 Sep; 810():70-82. PubMed ID: 28583430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma.
    Babu R; Adamson DC
    Core Evid; 2012; 7():93-103. PubMed ID: 23055947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non-small cell lung cancer.
    Akazawa Y; Saito Y; Yoshikawa T; Saito K; Nosaka K; Shimomura M; Mizuno S; Nakamoto Y; Nakatsura T
    Cancer Sci; 2020 Aug; 111(8):2736-2746. PubMed ID: 32391625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme.
    Del Vecchio CA; Wong AJ
    Curr Opin Mol Ther; 2010 Dec; 12(6):741-54. PubMed ID: 21154166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospect of rindopepimut in the treatment of glioblastoma.
    Elsamadicy AA; Chongsathidkiet P; Desai R; Woroniecka K; Farber SH; Fecci PE; Sampson JH
    Expert Opin Biol Ther; 2017 Apr; 17(4):507-513. PubMed ID: 28274144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Clonal Neoantigens Derived From Driver Mutations in an
    Wu D; Liu Y; Li X; Liu Y; Yang Q; Liu Y; Wu J; Tian C; Zeng Y; Zhao Z; Xiao Y; Gu F; Zhang K; Hu Y; Liu L
    Front Immunol; 2020; 11():1366. PubMed ID: 32793190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decoupled neoantigen cross-presentation by dendritic cells limits anti-tumor immunity against tumors with heterogeneous neoantigen expression.
    Nguyen KB; Roerden M; Copeland CJ; Backlund CM; Klop-Packel NG; Remba T; Kim B; Singh NK; Birnbaum ME; Irvine DJ; Spranger S
    Elife; 2023 Aug; 12():. PubMed ID: 37548358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
    Medikonda R; Pant A; Lim M
    Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoantigen Cancer Vaccines and Different Immune Checkpoint Therapies Each Utilize Both Converging and Distinct Mechanisms that in Combination Enable Synergistic Therapeutic Efficacy.
    Keshari S; Shavkunov AS; Miao Q; Saha A; Williams CD; Highsmith AM; Pineda JE; Alspach E; Hu KH; Pauken KE; Chen K; Gubin MM
    bioRxiv; 2024 Jan; ():. PubMed ID: 38187708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review.
    Liu L; Wang C; Li S; Bai H; Wang J
    Transl Lung Cancer Res; 2021 Sep; 10(9):3823-3839. PubMed ID: 34733631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progastrin-Releasing Peptide Precursor and Neuron-Specific Enolase Predict the Efficacy of First-Line Treatment with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors Among Non-Small-Cell Lung Cancer Patients Harboring EGFR Mutations.
    Dong J; Tong S; Shi X; Wang C; Xiao X; Ji W; Sun Y
    Cancer Manag Res; 2020; 12():13607-13616. PubMed ID: 33447080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer.
    Aparicio B; Repáraz D; Ruiz M; Llopiz D; Silva L; Vercher E; Theunissen P; Tamayo I; Smerdou C; Igea A; Santisteban M; Gónzalez-Deza C; Lasarte JJ; Hervás-Stubbs S; Sarobe P
    Front Immunol; 2022; 13():985886. PubMed ID: 36405725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    Hsu PC; Jablons DM; Yang CT; You L
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.